Clinical factors associated with growth and neoantigen reactivity of tumor infiltrating lymphocytes from metastatic epithelial cancers.

ABSTRACT:

Background

Adoptive cell therapy with tumor infiltrating lymphocytes is FDA approved for metastatic melanoma. TIL from patients with melanoma and factors relating to growth and reactivity have been studied; however, this has not been explored in patients with epithelial cancers.

Patients and methods

Metastatic epithelial tumors resected for TIL growth from 2014 to 2023 were analyzed. Two hundred and ninety-one operations were performed to collect TIL for potential treatment. Of these, 263 harvests were each processed for up to 24 individual fragment cultures and screened for neoantigen recognition of the expressed products of cancer mutations. Patient and tumor characteristics were collected. Endpoints were growth (defined as more than half of all fragment cultures expanded

SUBMITTER: Gustafson AM 

PROVIDER: S-EPMC12179044 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature